(Q46567099)

23 December 2017

title

Short-term, high dose enzyme replacement therapy in sialidosis mice (English)

1 reference

23 December 2017

enzyme replacement therapy

main subject

0 references

1 reference

Dongning Wang

1

1 reference

23 December 2017

Erik J Bonten

2

1 reference

23 December 2017

Gouri Yogalingam

3

1 reference

23 December 2017

Linda Mann

4

1 reference

23 December 2017

Alessandra d'Azzo

5

1 reference

23 December 2017

publication date

25 April 2005

1 reference

23 December 2017

Molecular Genetics and Metabolism

published in

1 reference

23 December 2017

volume

85

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

181-189

1 reference

23 December 2017

Enzyme-replacement therapy for metabolic storage disorders

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme-replacement therapy in mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme therapy for Gaucher disease: the first 5 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Expression of mannose 6-phosphate receptors in chicken

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Control of insulin-like growth factor-II/mannose 6-phosphate receptor gene transcription by proximal promoter elements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Developmental expression of the IGF-II/mannose 6-phosphate receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Lysosomal neuraminidase. Catalytic activation in insect cells is controlled by the protective protein/cathepsin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Three-dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Double staining of immunoblot using enzyme histochemistry and India ink.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Recent development in mammalian sialidase molecular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme replacement and enhancement therapies for lysosomal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Gene therapy progress and prospects: gene therapy of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Enzyme replacement therapy in feline mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Adult-onset lysosomal storage disease in a Schipperke dog: clinical, morphological and biochemical studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Immune response to enzyme replacement therapy: clinical signs of hypersensitivity reactions and altered enzyme distribution in a high titre rat model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.03.007

10.1016/J.YMGME.2005.03.007

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

15979029

1 reference

23 December 2017